GSK Pharma Q4 net profit rises 16.56 percent to Rs 123 crore
The company had posted a net profit of Rs 105.55 crore for the corresponding period of the previous fiscal, GSK said in a filing to the BSE.
New Delhi: Drug firm Glaxo Smith Kline Pharmaceuticals Monday reported a 16.56 per cent rise in its standalone net profit to Rs 123.03 crore for the quarter ended March 31.
The company had posted a net profit of Rs 105.55 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
Read Also: GSK Consumer Healthcare Q4 profit up 35 percent to Rs 285 crore
For the fiscal year ended March this year, the company posted a net profit of Rs 425.36 crore as against Rs 351.98 crore for the previous fiscal year.
Standalone revenue from operations for the fiscal year ended March 2019 stood at Rs 3,128.53 crore. It was Rs 2,895.88 crore for the year-ago fiscal.
Read Also: Patent Infringement: Vectura wins case against GSK; awarded $89.7 million in damages
The company said its board has recommended a dividend of Rs 20 per equity share on a face value of Rs 10 each for the year ended March 31.
Shares of Glaxo Smith Kline Pharmaceuticals were trading at Rs 1,280 per scrip on the BSE, up 0.66 per cent from its previous close.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd